Connection

MICHELE REDELL to Antineoplastic Agents

This is a "connection" page, showing publications MICHELE REDELL has written about Antineoplastic Agents.
Connection Strength

0.775
  1. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. Br J Haematol. 2015 Sep; 170(5):704-18.
    View in: PubMed
    Score: 0.258
  2. Targeting transcription factors for cancer therapy. Curr Pharm Des. 2005; 11(22):2873-87.
    View in: PubMed
    Score: 0.126
  3. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 01; 42(7):821-831.
    View in: PubMed
    Score: 0.117
  4. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. Clin Transl Oncol. 2021 Oct; 23(10):2141-2154.
    View in: PubMed
    Score: 0.098
  5. Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors. Org Biomol Chem. 2020 05 06; 18(17):3288-3296.
    View in: PubMed
    Score: 0.091
  6. Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity. Angew Chem Int Ed Engl. 2015 Oct 26; 54(44):13085-9.
    View in: PubMed
    Score: 0.066
  7. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics. 2018; 8(8):2189-2201.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.